Endocrinology, Vol 116, 2174-2178, Copyright © 1985 by Endocrine Society

ARTICLES

Antiserum to rat growth hormone (GH)-releasing factor suppresses but does not abolish antisomatostatin-induced GH release in the rat

CR Thomas, K Groot and A Arimura

Injection of SRIF antiserum (oA-SRIF) increases serum GH and TSH levels in urethane-anesthetized rats. These responses require an intact hypothalamus with endogenous GH-releasing factor (GHRF) or TRH, respectively. We examined whether pretreatment of rats with an antiserum against rat GHRF (oA-rGHRF) would abolish the GH response to oA-SRIF, since anti-TRH serum has been shown to abolish TSH response to oA-SRIF. Prior injection of oA-rGHRF reduced oA-SRIF-induced GH response in a dose-related manner in a dose up to 1 ml antiserum, but failed to produce any further suppression at higher doses. The maximum suppression of the GH response was approximately 50%. oA-rGHRF also suppresses basal GH levels significantly. On the other hand, oA-rGHRF completely abolished the GH-releasing activity of 1 microgram synthetic rGHRF when incubated for 30 min at room temperature before injection. The results suggest two conclusions: 1) 43-residue rGHRF is a physiological regulator of both basal and stimulated GH release; 2) failure of oA-rGHRF to completely abolish the GH response to oA-SRIF suggests the presence of other physiological GHRFs in the rat.

This article has been cited by other articles:

				L. S. Farhy and J. D. Veldhuis Putative GH pulse renewal: periventricular somatostatinergic control of an arcuate-nuclear somatostatin and GH-releasing hormone oscillator Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2004; 286(6): R1030 - R1042. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, S. M. Anderson, J. T. Patrie, and C. Y. Bowers Estradiol Supplementation in Postmenopausal Women Doubles Rebound-Like Release of Growth Hormone (GH) Triggered by Sequential Infusion and Withdrawal of Somatostatin: Evidence that Estrogen Facilitates Endogenous GH-Releasing Hormone Drive J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 121 - 127. [Abstract] [Full Text] [PDF]

				E. V. Dimaraki, C. A. Jaffe, C. Y. Bowers, P. Marbach, and A. L. Barkan Pulsatile and nocturnal growth hormone secretions in men do not require periodic declines of somatostatin Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E163 - E170. [Abstract] [Full Text] [PDF]

				E. V. Dimaraki, C. A. Jaffe, R. Demott-Friberg, M. Russell-Aulet, C. Y. Bowers, P. Marbach, and A. L. Barkan Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E489 - E495. [Abstract] [Full Text] [PDF]

				C. Lanneau, M. T. Bluet-Pajot, P. Zizzari, Z. Csaba, P. Dournaud, L. Helboe, D. Hoyer, E. Pellegrini, G. S. Tannenbaum, J. Epelbaum, et al. Involvement of the Sst1 Somatostatin Receptor Subtype in the Intrahypothalamic Neuronal Network Regulating Growth Hormone Secretion: An in Vitro and in Vivo Antisense Study Endocrinology, March 1, 2000; 141(3): 967 - 979. [Abstract] [Full Text] [PDF]

				W. R. Baumbach, T. A. Carrick, M. H. Pausch, B. Bingham, D. Carmignac, I. C. A. F. Robinson, R. Houghten, C. M. Eppler, L. A. Price, and J. R. Zysk A Linear Hexapeptide Somatostatin Antagonist Blocks Somatostatin Activity In Vitro and Influences Growth Hormone Release in Rats Mol. Pharmacol., November 1, 1998; 54(5): 864 - 873. [Abstract] [Full Text]